Testosterone and Cardiovascular Risk: TRAVERSE Trial and New FDA Label Change
Mohit Khera, MD, MBA, MPH, discusses testosterone therapy and cardiovascular risk, focusing on the TRAVERSE trial and FDA label changes.
Read MoreSelect Page
Posted by Mohit Khera, MD, MBA, MPH | Apr 2025
Mohit Khera, MD, MBA, MPH, discusses testosterone therapy and cardiovascular risk, focusing on the TRAVERSE trial and FDA label changes.
Read MorePosted by Christian P. Pavlovich, MD | Apr 2025
Christian P. Pavlovich, MD, examines the use of TULSA in prostate cancer treatment, highlighting its technique, outcomes, and future potential.
Read MorePosted by Jay Simhan, MD, FACS | Apr 2025
Jay Simhan, MD, FACS, explores the challenges of post-radiation bladder neck and proximal urethral strictures.
Read MorePosted by Sigrid V. Carlsson, MD, PhD, MPH | Apr 2025
Sigrid V. Carlsson, MD, PhD, MPH, explores the role of genetics in risk-stratified prostate cancer screening.
Read MorePosted by William K. Oh, MD | Apr 2025
William K. Oh, MD, explores neuroendocrine prostate cancer, emphasizing its increasing prevalence and aggressive nature.
Read More